Several elements of making cell therapies create significant obstacles in getting these treatments to more patients.
“A main challenge for cell therapies—autologous or allogeneic—is cryopreservation in the supply chain,” says Simona Guidi, business development director at Rigenerand. “Products have a very short shelf life, sometimes hours or days.”
That obstacle prevents many patients from getting such treatments. A potential solution involves getting the production closer to patients. “That is a big issue,” points out Guidi.
